DaVita Inc.

The grade, in three tenses

Headline 6.4 out of ten, 9 of 9 metrics filed: past 7.1 out of ten, present 6.4 out of ten, future 5.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

• Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2017. 82nd percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Track record (past): 5.6 out of ten. +2.7% a year over 10 filed years; profitable in 10 of 10. 56th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Shareholder treatment (past): 8.7 out of ten. Share count shrank 7.5% a year. 50% of cash flow returned. Insiders: 9 sales, 0 purchases. 87th percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Financial health (present): 5.5 out of ten. Leverage 104%: owes 104¢ per asset dollar. 55th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Industry position (present): 6.5 out of ten. top 35% of 10 in its family; net margin 5.5%. 65th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Leadership (present): 7.7 out of ten. top 23% of 7 in its family for leadership; chief executive since 2014. 77th percentile among 7 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
• Room to expand (future): 3.5 out of ten. bottom 35% of 10 in its family for room to expand. 35th percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Growth drivers (future): 7.2 out of ten. top 28% of 10 in its family for growth drivers. 72nd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
• Expectations vs reality (future): 5.2 out of ten. top 48% of 10 in its family for expectations against reality. 52nd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-11 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-04 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-04 (on EDGAR). Newest filing: Form 4, 2026-09-24. Filings on record since 1996. Read from EDGAR 2026-10-12.

Where the revenue comes from

Lines of business in fiscal 2025: US Dialysis and Related Lab Services 86%, All Other 14%. As tagged in its annual report (Form 10-K, filed 2026-02-11).

Who runs it

Rodriguez, Javier (Chief Executive Officer); Ackerman, Joel (CFO and Treasurer); Maughan, David Paul (Chief Operating Officer, DKC); Waters, Kathleen Alyce (Chief Legal & Pub. Affairs Off); Hearty, James O (Chief Compliance Officer); Berry, Christopher Michael (Chief Accounting Officer); Arway, Pamela M (director); Desoer, Barbara J (director); Hollar, Jason M. (director); Moore, Gregory J. (director); and 4 more. 14 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.